BIOMAX-INFORMATICS
7.4.2021 10:02:13 CEST | Business Wire | Press release
Biomax Informatics announces the launch of version 2.0 of AILANI. AILANI 2.0 represents an even more modern and user-friendly version of Biomax Informatics’ semantic search platform. Via the new AILANI Cloud Interface, users can quickly and cost-effectively search through numerous publicly accessible, academic full-text documents, news feeds, clinical studies, and COVID-19-relevant patents, receiving intelligent responses to their questions, alongside their keyword search. Unlike in the first version of AILANI, people using the AILANI Cloud benefit from a document tagging system for collaborative purposes, as well as from the introduction of “personas,” which enable a different experience for distinct user groups.
Through the new AILANI Enterprise solution, Biomax also offers customers the opportunity to integrate their own data – in both a structured and unstructured format – into the system, to expand the semantic search function to this data by means of AI algorithms, and to compare it with publicly accessible data. To increase acceptance among employees and to optimize integration into the system landscape, the portal can be quickly and easily adapted to the company’s corporate design. An optional group function (persona) enables the rapid exchange of data and responses within the team. This allows new ideas and new knowledge to be generated and shared more quickly. The time required for product development can be reduced considerably, decisions can be made more rapidly and in an enhanced manner, and competitive advantages can be realized.
“The experiences and feedback of our customers over the past year have shown us that we can make a valuable contribution to successful research and product development in the life sciences sector through AILANI,” says Dr. Sascha Losko, Director of Product Management. “With AILANI 2.0 and our new pricing model, we are also able to provide companies of any size with optimal access to our software.”
Through AILANI for COVID-19, Biomax Informatics began offering free access to AILANI back in spring 2020. Interested parties can try out AILANI for free at https://ailani.ai and get answers to specific questions relating to COVID-19.
Free Webinar about AILANI 2.0
Biomax will offer a free webinar on AILANI 2.0 at 3:00 p.m. on April 29, 2021. For more information, please visit our website at www.biomax.com/webinar or follow us on LinkedIn. Biomax experts are already looking forward to providing attendees with a detailed insight into AILANI 2.0.
About Biomax Informatics:
Biomax Informatics offers software solutions for better decision-making and optimal knowledge management in the life sciences industry. Using the company’s software, customers can generate added value through the integration of information from their own and public resources, enabling them to achieve a knowledge-based approach for the development of innovative life sciences products. Biomax’s global customers include clinics, companies, and research institutions successful in the fields of research into active substances, diagnostics, fine chemicals, and food and plant products. The company, which was founded in 1997 and currently has 45 members of staff, is headquartered in Planegg near Munich. Further information can be found at www.biomax.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210407005042/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mexico Becomes the First Market Worldwide to Receive Approval for Galderma’s Restylane® Shaype™ for Both Chin and Its First Jawline Indication13.11.2026 07:00:00 CET | Press release
Restylane Shaype is now approved in Mexico for temporary augmentation in the chin area and improvement of jawline definition,1 with launch anticipated in H1 2027 Already approved across various markets globally for the chin area,2 this marks Restylane Shaype’s first approval for the jawline worldwide1 The first-and-only shaper on the hyaluronic acid (HA) market, Restylane Shaype features the firmest HA gel available and is powered by proprietary NASHA HD™ technology, developed to build and shape on bone for instant, natural-looking contour and definition3-6 The approval reinforces Galderma's commitment to advancing innovation in the HA category, enabling the company to meet diverse patient needs Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that Restylane Shaype has been approved for temporary augmentation in the chin area and improvement of jawline definition in Mexico.1 This is the product’s first approval globally for the jawline, and further expan
vVARDIS Announces Pricing of Initial Public Offering13.11.2026 06:02:00 CET | Press release
vVARDIS Holding AG (“vVARDIS”), a Swiss healthcare company operating in the dental med-tech sector, today announced the pricing of its initial public offering of 9,722,223 Class A ordinary shares at a public offering price of $18.00 per share. In connection with the offering, vVARDIS has granted the underwriters a 30-day option to purchase up to an additional 1,458,333 Class A ordinary shares at the initial public offering price to cover over-allotments. The Class A ordinary shares are expected to begin trading on the New York Stock Exchange on November 13, 2026 under the symbol “VVVV.” The closing of the offering is expected to occur on or about November 16, 2026 subject to the satisfaction of customary closing conditions. Goldman Sachs & Co. LLC and J.P. Morgan are acting as joint bookrunning managers for the offering, with William Blair, UBS Investment Bank and Deutsche Bank Securities acting as bookrunners. A registration statement on Form F-1 relating to the offering has been file
Empire State Building Observation Deck to Debut ‘Olympus Awaits,’ An Immersive ‘Percy Jackson and the Olympians’ Takeover in the Heart of NYC, On Display from Nov. 16 – Dec. 4*12.11.2026 23:07:00 CET | Press release
The multi-level takeover includes a Throne Room, interactive photo opportunities, special lighting, and more The Empire State Building (ESB) is the gateway to Mount Olympus in Percy Jackson’s world, and now fans can experience the magic like never before. On Nov. 16, the Empire State Building Observation Deck (ESBOD) will unveil “Olympus Awaits,” a multi-level “Percy Jackson and the Olympians” takeover, in partnership with Disney+. The immersive takeover – included with every Observation Deck ticket – will feature an epic Throne Room, interactive photo opportunities, surprise giveaways, ESB x “Percy Jackson” merch, and more, available through Dec. 4, 2026.* This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112442266/en/ Empire State Building Observation Deck to Debut ‘Olympus Awaits,’ An Immersive ‘Percy Jackson and the Olympians’ Takeover in the Heart of NYC, On Display from Nov. 16 – Dec. 4* “This immersive NYC experience
Clene Nanomedicine Partners with Veristat to Reduce Biostatistical Output Time by 80% for ALS New Drug Application12.11.2026 18:09:00 CET | Press release
Veristat’s InStat™ delivers submission-ready tables, listings, and figures (TLFs) in one week using validated statistical engines, shortening the critical path from database lock to submission VeristatTM, a global clinical research organization (CRO) and consultancy specializing in complex studies, announced that it has partnered with Clene Nanomedicine to cut the time to deliver biostatistical outputs for a pivotal ALS drug application submission by 80%. Veristat reduced the time from study data to validated tables, listings and figures (TLFs) from up to six weeks to just one week. Clene, a late-stage biotech company, leveraged Veristat’s recently launched InStat™ platform, the industry’s first zero-code, fully automated solution to accelerate clinical trial processes. Biostatistical TLFs sit on the critical path for submissions, yet most sponsors rely on antiquated processes that involve slow, manual workflows to produce them, making post-database lock one of the biggest bottlenecks
WHOOP Launches WHOOP Humans, the Most Verifiably Human Social Network12.11.2026 18:00:00 CET | Press release
New feature lets members follow friends and family, share performance and health insights, and celebrate life's moments together WHOOP, the human performance brand, today launched WHOOP Humans, a new feature that lets members follow friends and family, share fitness, health, and performance data they choose, and support each other's progress. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112176779/en/ WHOOP Launches WHOOP Humans, the Most Verifiably Human Social Network For more than a decade, WHOOP has helped members better understand their own health and performance. Now, WHOOP Humans extends that experience beyond the individual, making it easier to celebrate achievements, encourage progress, and look out for the people who matter most. "In a world that's becoming increasingly artificial, we're building something deeply human,” said Will Ahmed, Founder and CEO of WHOOP. “This is the most verifiably human network ever
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom